Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria

References

• Ware RE, de Montalembert M, Tshilolo L, et al. Sickle cell disease. Lancet. 2017;390(10091):311–323.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Nagel RL. Sickle-cell disease. Lancet. 2004;364(9442):1343–1360.
   PubMed Web of Science ®Google Scholar
• Rees DC. The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica. 2011;96(4):488–491.
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Heeney MM. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer. 2012;59(2):365–371.
   PubMed Web of Science ®Google Scholar
• Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
   PubMed Web of Science ®Google Scholar
• Lebensburger JD, Pestina TI, Ware RE, et al. Hydroxyurea therapy requires Hb F induction for clinical benefit in a sickle cell mouse model. Haematologica. 2010;95(9):1599–1603.
   PubMed Web of Science ®Google Scholar
• Elford HL. Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun. 1968;33(1):129–135.
   PubMed Web of Science ®Google Scholar
• Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: what doesn’t kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057–1072.
   PubMed Web of Science ®Google Scholar
• Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008;358(13):1362–1369.
   PubMed Web of Science ®Google Scholar
• Nébor D, Romana M, Santiago R, et al. Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica. 2013;98(6):862–867.
   PubMed Web of Science ®Google Scholar
• Green NS, Barral S. Emerging science of hydroxyurea therapy for pediatric sickle cell disease. Pediatr Res. 2014;75(1-2):196–204.
   PubMed Web of Science ®Google Scholar
• Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130(24):2585–2593.
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–419.
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131.
   PubMed Web of Science ®Google Scholar
• Cunningham Myrie C, Abdulkadri A, Waugh A, et al. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: a cost effectiveness analysis. Pediatr Blood Cancer. 2015;62(10):1862–1864.
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670.
   PubMed Web of Science ®Google Scholar
• Lagunju I, Brown BJ, Sodeinde O. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort. Pediatr Blood Cancer. 2015;62(9):1587–1591.
   PubMed Web of Science ®Google Scholar
• McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?. Curr Opin Hematol. 2011;18(3):158–165.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
   PubMed Web of Science ®Google Scholar
• Zumberg MS, Reddy S, Boyette RL, et al. Hydroxyurea therapy for sickle cell disease in community-based practices: a survey of Florida and North Carolina hematologists/oncologists. Am J Hematol. 2005;79(2):107–113.
   PubMed Web of Science ®Google Scholar
• Brandow AM, Brousseau DC, Panepinto JA. Postdischarge pain, functional limitations and impact on caregivers of children with sickle cell disease treated for painful events. Br J Haematol. 2009;144(5):782–788.
   PubMed Web of Science ®Google Scholar
• Flanagan JM, Howard TA, Mortier N, et al. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. Mutat Res/Genet Toxicol Environ Mutagen. 2010;698(1):38–42.
   PubMed Web of Science ®Google Scholar
• McGann PT, Howard TA, Flanagan JM, et al. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011;154(1):134–140.
   PubMed Web of Science ®Google Scholar
• Agrawal RK, Patel RK, Shah V, et al. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus. 2014;30(2):91–96.
   PubMed Web of Science ®Google Scholar
• Lobo CL, Pinto JF, Nascimento EM, et al. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol. 2013;161(6):852–860.
   PubMed Web of Science ®Google Scholar
• Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010;85(6):403–408.
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.
   PubMed Web of Science ®Google Scholar
• Agbaraji V, Scott R, Leto S, et al. Fertility studies in sickle cell disease: semen analysis in adult male patients. Int J Fertil. 1988;33(5):347–352.
   PubMedGoogle Scholar
• Berthaut I, Guignedoux G, Kirsch-Noir F, et al. Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males. Haematologica. 2008;93(7):988–993.
   PubMed Web of Science ®Google Scholar
• Sahoo LK, Kullu BK, Patel S, et al. Study of seminal fluid parameters and fertility of male sickle cell disease patients and potential impact of hydroxyurea treatment. J Assoc Physicians India. 2017;65:22.
   PubMedGoogle Scholar
• Evenson D, Jost L. Hydroxyurea exposure alters mouse testicular kinetics and sperm chromatin structure. Cell Prolif. 1993;26(2):147–159.
   PubMed Web of Science ®Google Scholar
• Jones KM, Niaz MS, Brooks CM, et al. Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints. IJERPH. 2009;6(3):1124–1144.
   Web of Science ®Google Scholar
• Abudu EK, Akanmu SA, Soriyan OO, et al. Serum testosterone levels of Hb SS (sickle cell disease) male subjects in Lagos, Nigeria. BMC Res Notes. 2011;4(1):298.
   PubMedGoogle Scholar
• McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia. Expert Opin Drug Saf. 2015;14(11):1749–1758.
   PubMed Web of Science ®Google Scholar
• Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101(10):1046–1051.
   PubMed Web of Science ®Google Scholar
• Ghafuri DL, Stimpson S-J, Day ME, et al. Fertility challenges for women with sickle cell disease. Expert Rev Hematol. 2017;10(10):891–901.
   PubMed Web of Science ®Google Scholar
• Galadanci NA, Umar AS, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017;92(8):780–788.
   PubMed Web of Science ®Google Scholar